PD-1/PD-L1 Blockade in the Treatment of Nasopharyngeal Carcinoma

Guanfang Liu, Jessica M. Sido, Erxia Shen

Abstract


Programmed cell death-1(PD-1)/Programmed cell death ligand-1 (PD-L1) immune check blockade is one remarkable advance in cancer immunotherapy treatment. Clinical trials studying the efficacy of PD-1 blockade alone or combination with other therapy in different types of cancer have been evaluated or are under observation. Nasopharyngeal carcinoma, also called Cantonese cancer, occurs rarely in the western countries but is common in the tumors of head and neck in the South China. NPC is one type of head and neck tumors, but it is quite distinct among the head and neck tumors. Here, we would like to summarize the progress of PD-1/PD-L1 blockade in the treatment of nasopharyngeal carcinoma.

Full Text:

PDF Citation


DOI: http://dx.doi.org/10.15383/jnpc.36

Refbacks

  • There are currently no refbacks.

Comments on this article

View all comments


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

eISSN: 2312-0398

Asia Press is a professional Science, Technology and Medicine publisher, who owns rapid publication, Peer-Reviewed, Open Access Journals. Asia Press aims to promote “knowledge sharing”. As you know, the main barrier for free “knowledge sharing” is the cost of publishing and transfer. In order to encourage scholars and scientists to the max, and devote whole power to realize the aim of “knowledge sharing” and the benefit of “all” mankind, Asia Press performs a permanent policy of no charge for publication and access, and always open its door for authors worldwide.

© 2013-2017 by the Asia Press. All rights reserved.